Pricing
Prices are indicative MRP and may vary by pharmacy. Trend compares against the last recorded price.
All price changes →Indications & Uses
Agafi is indicated for:
Pharmacology
Aflibercept is a recombinant fusion protein. It is made from parts of the extracellular domains of human VEGF receptors 1 and 2, joined to the Fc portion of human IgG1, and it is prepared as an iso-osmotic solution for intravitreal use. The molecule is a dimeric glycoprotein. Its protein part has a molecular weight of 97 kilodaltons (kDa), and glycosylation adds another 15% of the total molecular mass, which brings the total molecular weight to 115 kDa. Aflibercept is produced in recombinant Chinese hamster ovary (CHO) cells.
It works as a soluble decoy receptor. It binds VEGF-A and PlGF, and in doing so it can stop these from binding to and activating their cognate VEGF receptors.
Dosage Reference
Reference Information Only
Dosages shown are general references from official sources. Always consult your doctor or pharmacist for personalized dosing.
Adults:
Neovascular (Wet) Age-Related Macular Degeneration (AMD)
The recommended dose of Aflibercept is 2 mg (0.05 mL), given by intravitreal injection every 4 weeks (approximately every 28 days, monthly) for the first 3 months. After that, the same 2 mg (0.05 mL) is given once every 8 weeks (2 months). The injection may be given as often as 2 mg every 4 weeks (approximately every 25 days, monthly), but in most patients this showed no additional efficacy compared with dosing every 8 weeks. Some patients may need dosing every 4 weeks (monthly) after the first 12 weeks (3 months). After one year of effective therapy, patients may also be treated with one dose every 12 weeks, though this is not as effective as the recommended every 8 weeks regimen. Patients should be assessed regularly.
Macular Edema Following Retinal Vein Occlusion (RVO)
The recommended dose is 2 mg (0.05 mL), given by intravitreal injection once every 4 weeks (approximately every 25 days, monthly).
Diabetic Macular Edema (DME) and Diabetic Retinopathy (DR)
The recommended dose of Aflibercept is 2 mg (0.05 mL), given by intravitreal injection every 4 weeks (approximately every 28 days, monthly) for the first 5 injections. After that, 2 mg (0.05 mL) is given once every 8 weeks (2 months). It may be given as often as 2 mg every 4 weeks (approximately every 25 days, monthly), but in most patients this showed no additional efficacy compared with dosing every 8 weeks. Some patients may need dosing every 4 weeks (monthly) after the first 20 weeks (5 months).
Side Effects
People who received Aflibercept Intravitreal Injection most often reported conjunctival hemorrhage, eye pain, cataract, vitreous detachment, vitreous floaters, retinal pigment epithelial tear and increased intraocular pressure. Each of these was reported by 5% or more of patients.
Cautions & Contraindications
Warnings & Precautions
Endophthalmitis, retinal pigment epithelial tear and retinal detachment can happen after an intravitreal injection such as Aflibercept. Patients should be told to report any symptoms that suggest endophthalmitis or retinal detachment without delay, and these should be managed appropriately. The pressure inside the eye (intraocular pressure) has been seen to rise within 60 minutes of an injection. There is also a potential risk of arterial thromboembolic events after intravitreal use of VEGF inhibitors.
Contraindications
Aflibercept Intravitreal Injection must not be used in people who are hypersensitive to aflibercept or to any of the excipients. It must also not be used when there is an active or suspected infection in or around the eye, or active severe inflammation inside the eye.
Pregnancy & Breastfeeding
Pregnancy: No adequate and well-controlled studies of Aflibercept have been done in pregnant women. In rabbits, Aflibercept caused harmful effects on the embryo and fetus, including external, visceral and skeletal malformations.
Lactation: Nothing is known about whether aflibercept passes into human milk. There is also no information on what the drug does to a breastfed infant, or on milk production and excretion.
Females and males of reproductive potential: Women who could become pregnant are advised to use effective contraception before the first dose, throughout treatment, and for at least 3 months after the last intravitreal injection of Aflibercept.
Infertility: There are no data on the effect of Aflibercept on human fertility.
⚠️ Talk to your doctor before taking any medicine during pregnancy or while breastfeeding.
Storage
Keep Aflibercept Intravitreal Injection in a refrigerator at 2ºC to 8ºC. Don't freeze it. Protect it from light, and keep it out of the reach of children.
Common questions about Agafi 2 mg/0.05 ml
What is Agafi 2 mg/0.05 ml Intravitreal Injection?
Agafi 2 mg/0.05 ml Intravitreal Injection is a medicine that contains Aflibercept Intravitreal Injection. It is made by Incepta Pharmaceuticals Ltd. It belongs to the Other ophthalmic preparations group of medicines.
What is Agafi used for?
Agafi is used for: Edema.
What are the side effects of Agafi?
People who received Aflibercept Intravitreal Injection most often reported conjunctival hemorrhage, eye pain, cataract, vitreous detachment, vitreous floaters, retinal pigment epithelial tear and increased intraocular pressure. Each of these was reported by 5% or more of patients.
Can I take Agafi during pregnancy or while breastfeeding?
Pregnancy: No adequate and well-controlled studies of Aflibercept have been done in pregnant women. In rabbits, Aflibercept caused harmful effects on the embryo and fetus, including external, visceral and skeletal malformations. Talk to your doctor before taking any medicine during pregnancy or while breastfeeding.
How should I store Agafi?
Keep Aflibercept Intravitreal Injection in a refrigerator at 2ºC to 8ºC. Don't freeze it.
Do I need a prescription for Agafi?
Agafi is a prescription (Rx) medicine. Take it as your doctor advises.